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that vary in severity. Linaclotide, a guanylate cyclase-C agonist, improves abdominal and bowel
symptoms in these patients. We examined the prevalence of severe abdominal symptoms in
patients with IBS-C and assessed the effects of linaclotide on abdominal symptoms, global
measures, and quality of life (QOL).METHODS: In two phase 3 trials, patients who met modiﬁed Rome II criteria for IBS-C were randomly
assigned to groups given oral, once-daily linaclotide (290 mg) or placebo for 12 weeks. During
the baseline (2 weeks prior to treatment) and treatment periods, patients rated abdominal
pain, discomfort, bloating, fullness, and cramping daily (from 0 [ none to 10 [ very severe).
Linaclotide’s effects on abdominal symptoms, global measures, and IBS-related QOL were
assessed in subpopulations of patients who rated speciﬁc individual abdominal symptoms as
severe (‡7.0) at baseline.RESULTS: In the intent-to-treat population (1602 patients; 797 receiving placebo and 805 receiving
linaclotide), baseline prevalence values for severe abdominal symptoms were 44% for bloating,
44% for fullness, 32% for discomfort, 23% for pain, and 22% for cramping, with considerable
overlap among symptoms. In patients with severe symptoms, linaclotide reduced all abdominal
symptoms; mean changes from baseline severity scores ranged from –2.7 to –3.4 for linaclotide
vs –1.4 to –1.9 for placebo (P < .0001). Linaclotide improved global measures (P < .0001) and
IBS-QOL scores (P < .01) compared with placebo. Diarrhea was the most common adverse event
of linaclotide in patients with severe abdominal symptoms (18.8%–21.0%).CONCLUSIONS: Of 5 severe abdominal symptoms assessed, bloating and fullness were most prevalent in pa-
tients with IBS-C. Linaclotide signiﬁcantly improved all abdominal symptoms, global measures,
and IBS-QOL in subpopulations of IBS-C patients with severe abdominal symptoms.
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phosphate; CMH, Cochran–Mantel-Haenszel; GC-C, guanylate cyclase-C;
IBS, irritable bowel syndrome; IBS-C, irritable bowel syndrome with con-
stipation; ITT, intent to treat; IVRS, interactive voice response system;
LOCF, last observation carried forward; NNT, number needed to treat;
NRS, numerical rating scale; QOL, quality of life.
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Open access under CC BY-NC-ND license.Irritable bowel syndrome (IBS) is a chronic func-tional gastrointestinal disorder affecting up to 15%
of the population in developed countries.1–3 IBS is
characterized by abdominal pain or discomfort associ-
ated with altered defecation4 and is classiﬁed on the
basis of predominant stool form into 4 subtypes: IBS
with diarrhea, IBS with constipation (IBS-C), mixed IBS,
and unsubtyped IBS.4
Patients with IBS-C often experience an array of
abdominal symptoms, including pain, discomfort, bloat-
ing, fullness, and cramping, that vary in severity. The
severity of abdominal symptoms has signiﬁcant clinical
implications because patients with more severe symp-
toms tend to use more health care resources, have worsehealth-related quality of life (QOL), and be less likely to
respond to treatment.5,6 Symptom severity is also an
important component of a patient’s perception of his/her
overall IBS severity.5 Despite the importance of symptom
April 2014 Linaclotide Effect on Severe IBS-C Symptoms 617severity, there are scant data regarding the prevalence of
symptoms that IBS-C patients rate as severe.
Linaclotide, a 14-amino acid peptide, is a guanylate
cyclase-C (GC-C) agonist that is structurally related to the
guanylin peptide family and is approved by the United
States Food and Drug Administration for the treatment of
IBS-C and chronic idiopathic constipation in adults and
by the European Medicines Agency for the treatment of
moderate to severe IBS-C in adults. Linaclotide binds to
and activates GC-C, resulting in the intracellular gener-
ation of cyclic guanosine monophosphate (cGMP), which
is then increased both intracellularly and extracellularly.
Data from animal models show that the increase in
intracellular cGMP results in a cascade of events leading
to increased ﬂuid secretion into the intestinal lumen and
accelerated gastrointestinal transit; the increase in extra-
cellular cGMP results in reduced visceral nociception.7,8
In two phase 3 clinical trials, linaclotide has been
shown to improve abdominal and bowel symptoms in
patients with IBS-C.9,10 However, the efﬁcacy of linaclo-
tide in IBS-C patients with severe symptoms has not
been examined. To address this issue, a post hoc analysis
of pooled data from the two phase 3 trials was conducted
with the following objectives: (1) to examine the baseline
prevalence of severe abdominal symptoms (pain,
discomfort, bloating, fullness, cramping) and (2) to
assess the effects of linaclotide on these symptoms, as
well as on global measures of improvement (adequate
relief, degree of relief, and treatment satisfaction) and
IBS-related QOL, in the subpopulations of IBS-C patients
with severe abdominal symptoms at baseline.
Methods
Trial Design
Detailed study methods for both phase 3 clinical trials
(Trials 31 and 302) have been recently published.9,10 In
brief, these multicenter, randomized, double-blind, pla-
cebo-controlled, parallel-group trials were identical
through the ﬁrst 12 weeks of treatment. The trials
included a 2-week baseline period that was followed by
randomization of patients in equal proportions to either
placebo or linaclotide 290 mg once daily during treat-
ment periods of either 12 weeks (Trial 31) or 26 weeks
(Trial 302). Primary end points were assessed for both
trials during the ﬁrst 12 weeks of treatment.
Trial Patients
Inclusion and exclusion criteria for the trials have
been published previously.9,10 Brieﬂy, female and male
patients were eligible to participate if they were at least
18 years of age and met modiﬁed Rome II criteria for
IBS-C.11 Patients had to have a mean score 3.0 for daily
abdominal pain at its worst (11-point numerical rating
scale [NRS]) as well as a mean of 5 spontaneous bowelmovements (a bowel movement [BM] occurring in the
absence of laxative, enema, or suppository use on the
calendar day of the BM or the calendar day before the
BM) per week and <3 complete spontaneous BMs (a
spontaneous BM that is associated with a sensation of
complete emptying) per week during the 2-week base-
line period.
Efﬁcacy Assessments and Severe
Subpopulation Criterion
Daily reports by patients to an interactive voice
response system (IVRS) included symptom ratings of
abdominal pain at its worst, abdominal discomfort,
abdominal bloating, abdominal fullness, and abdominal
cramping. All abdominal symptoms were measured by
using the 11-point NRS (example question: “How would
you rate your abdominal discomfort over the last 24
hours? Enter a number from 0 to 10, where 0 represents
no abdominal discomfort and 10 represents very severe
abdominal discomfort.”). The severe subpopulation for
each abdominal symptom included patients in the intent-
to-treat (ITT) population with a baseline score 7.012 for
that abdominal symptom. Patients were included in more
than 1 subpopulation if they had more than 1 abdominal
symptom scored 7.0 at baseline.
Weekly IVRS assessments of global measures of
improvement included adequate relief of IBS-C symp-
toms (yes/no) and degree of relief of IBS symptoms
(7-point balanced scale: 1 ¼ completely relieved, 4 ¼
unchanged, 7 ¼ as bad as I can imagine). Satisfaction
with the trial medication’s ability to relieve IBS symp-
toms (5-point ordinal scale: 1 ¼ not at all satisﬁed to 5 ¼
very satisﬁed) was assessed at all trial visits. The IBS-QOL,
a self-administered QOL instrument yielding an overall
score ranging from 0 (poor QOL) to 100 (maximum
QOL),13 was assessed at baseline and at week 12.
End Points
Change-from-baseline end points for abdominal
symptoms (pain, discomfort, bloating, fullness, and
cramping) were analyzed at week 12. Responder end
points for adequate relief of IBS-C symptoms, degree of
relief of IBS symptoms, treatment satisfaction, and IBS-
QOL overall score were also analyzed at week 12; the
number needed to treat (NNT) was calculated for each of
these end points. Adequate relief responders answered
“yes” to the question “Overall, have you had adequate
relief from your IBS symptoms during the past 7 days?”
Degree of relief responders had a degree of relief of IBS
symptoms score of 3 (somewhat relieved, considerably
relieved, or completely relieved) on the 7-point balanced
scale. Treatment satisfaction responders had a treatment
satisfaction score of 3 (moderately, quite, or very
satisﬁed) on the 5-point scale. IBS-QOL responders had a
change-from-baseline improvement of 14 points on the
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determined to be clinically meaningful on the basis of
previous research by Drossman et al.14 For all end points
analyzed, if a patient discontinued from the trial or had
missing data at week 12, a last-observation-carried-
forward (LOCF) method was applied; patients with no
post-baseline assessments of the end point were
excluded from the analysis.Safety Assessments
At each study visit, patients were asked an open-
ended question regarding adverse events (AEs). Pa-
tients reported AEs by recalling instances since their
prior visit. The site investigator recorded all patient-
reported AEs and judged each event for severity and
relationship to the blinded trial medication. Other safety
evaluations included physical examinations, electrocar-
diogram recordings, vital sign measurements, and stan-
dard clinical laboratory tests.Statistical Methods
All analyses were based on pooled results from the two
phase 3 trials. The safety population included patients who
received 1 dose of double-blind trial medication during
the treatment period. The ITT population included patients
in the safety population who had 1 post-randomization
assessment of abdominal pain or BM frequency.9,10
End points were evaluated in each severe abdominal
symptom subpopulation (baseline severity scores 7 on
the 11-point NRS; hereafter, severe subpopulation) andTable 1. Demographic and Baseline Clinical Characteristics
Severe abdomina
Severe pain
(n ¼ 376)
Severe discomfort
(n ¼ 507)
Demographic data
Age (y), mean (range) 43.2 (19–81) 43.2 (18–81)
65, n (%) 12 (3.2) 15 (3.0)
Sex, n (%)
Female 343 (91.2) 468 (92.3)
Male 33 (8.8) 39 (7.7)
Race, n (%)
White 285 (75.8) 390 (76.9)
Black 71 (18.9) 95 (18.7)
Other 20 (5.3) 22 (4.3)
Abdominal symptoms,a mean
Abdominal pain 8.0 7.5
Abdominal discomfort 8.2 8.0
Abdominal bloating 8.4 8.4
Abdominal fullness 8.4 8.4
Abdominal cramping 7.7 7.2
IBS-QOL overallb 51.3 52.2
aAssessed by using 11-point NRS: 0 ¼ none, 10 ¼ very severe.
bScore ranging from 0 (poor QOL) to 100 (maximum QOL).in the ITT population. Continuous change-from-baseline
end points were analyzed by using an analysis of
covariance (ANCOVA) model with treatment group,
geographic region, and study as factors and the corre-
sponding baseline value as a covariate. The change-from-
baseline means are least-squares means from the
corresponding ANCOVA model. Responder end points
were analyzed by using a Cochran–Mantel-Haenszel
(CMH) test controlling for study and geographic region.
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.Results
Analysis Populations and Demographics
The pooled ITT population comprised 1602 patients
(Table 1). The abdominal symptoms with the highest
prevalence of mean baseline severity scores 7.0 were
fullness and bloating (44% for both, Figure 1), followed
by discomfort (32%), pain (23%), and cramping (22%).
Because IBS-C patients generally experience multiple
abdominal symptoms, it is not surprising that there was
considerable overlap in these 5 severe subpopulations.
In particular, 90% of the patients in the bloating sub-
population were also in the fullness subpopulation and
vice versa (Figure 2A). Similarly, more than 80% of those
who reported severe pain also reported severe cramping
and vice versa (Figure 2B). The overlap was somewhat
less for other symptom pairings. Because of these over-
laps, efﬁcacy results will only be reported for 3 repre-
sentative subpopulations, the pain, discomfort, andl symptom subpopulations
ITT population
(N ¼ 1602)
Severe bloating
(n ¼ 702)
All 3 symptoms severe
(n ¼ 339)
43.4 (18–81) 43.6 (19–81) 43.9 (18–87)
22 (3.1) 12 (3.5) 85 (5.3)
666 (94.9) 314 (92.6) 1443 (90.1)
36 (5.1) 25 (7.4) 159 (9.9)
531 (75.6) 254 (74.9) 1240 (77.4)
147 (20.9) 66 (19.5) 301 (18.8)
24 (3.4) 19 ( 5.6) 61 (3.8)
6.8 8.1 5.6
7.4 8.3 6.1
8.3 8.6 6.6
8.2 8.5 6.6
6.5 7.7 5.3
55.5 50.4 61.1
Figure 1. Percentages of patients with mean baseline abdom-
inal symptomscore7.0. For each symptom, the percentage of
patients with a mean baseline score 7.0 is presented. The
denominator is the pooled ITT population (N ¼ 1602).
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population of ITT patients with baseline scores 7.0 for
all 3 of these abdominal symptoms (pain, discomfort, and
bloating; Figure 2C). Demographic characteristics were
similar between each of these 4 subpopulations and the
pooled ITT population, although the subpopulations
tended to be younger, more female, and more non-white
than the ITT population. Not surprisingly, the baseline
QOL as measured by the IBS-QOL was worse in the se-
vere subpopulations compared with the ITT population
(50 to 56 vs 61 on a 100-point scale; Table 1).
Efﬁcacy Results
In each of the 4 severe subpopulations, the mean
changes from baseline for abdominal pain, discomfort,Figure 2. Severe abdominal symptom subpopulations (mean ba
fullness subpopulations each represent 44% of the ITT populat
severe cramping subpopulations represent 23% and 22% of the
than 80%. (C) The severe bloating, severe discomfort, and seve
ITT population, respectively, and were chosen for analyses. Th
symptoms severe subpopulation that includes patients with
discomfort, and abdominal bloating (21% of the ITT populationbloating, fullness, and cramping were signiﬁcantly greater
for linaclotide-treated patients at week 12 compared with
placebo-treated patients (Table 2, P < .0001). In addition,
for each of these symptoms, the mean changes for
linaclotide-treated patients were higher in the severe
subpopulations than in the ITT population. Moreover, for
each of these symptoms, the corresponding differences
between linaclotide-treated and placebo-treated patients
(ie, the treatment effects) were higher in the severe sub-
populations than in the ITT population (Table 2).
For all 3 global responderendpoints, linaclotide-treated
patients in the severe subpopulations had signiﬁcantly
better response rates than placebo-treated patients. Across
the severe subpopulations, 59%–61% of linaclotide-
treated patients reported adequate relief of IBS
symptoms at week 12 compared with 28%–32% of
placebo-treated patients (Figure 3A, P < .0001 for linaclo-
tide vs placebo in all severe subpopulations); NNTs ranged
from 3.0–3.7. For degree of relief of IBS symptoms, 73%–
75% of linaclotide-treated patients reported that their
symptoms were somewhat, considerably, or completely
relieved at week 12 compared with 43%–47% of placebo-
treated patients (Figure 3B, P < .0001 for linaclotide vs
placebo in all severe subpopulations); NNTs ranged from
3.2–3.8. Likewise, 70%–77%of linaclotide-treated patients
reported being moderately, quite, or very satisﬁed with
treatment at week 12 compared with 41%–43% of
placebo-treated patients (Figure 3C, P < .0001 for linaclo-
tide vs placebo in all severe subpopulations); NNTs ranged
from 2.9–3.6. For the IBS-QOL analysis, 62%–68% of
linaclotide-treated patients were IBS-QOL responders,
compared with 45%–47% of placebo patients (Figure 3D,
P < .01 for linaclotide vs placebo in all severe sub-
populations); NNTs ranged from 4.7–6.0.seline severity score 7.0). (A) The severe bloating and severe
ion and overlap each other by 90%. (B) The severe pain and
ITT population, respectively, and overlap each other by more
re pain subpopulations represent 44%, 32%, and 23% of the
e intersection of these 3 subpopulations represents the all 3
mean baseline scores 7.0 for abdominal pain, abdominal
).
Table 2.Week 12 Change From Baseline in Abdominal Symptoms
Abdominal symptomsa
Severe abdominal symptom subpopulations
ITT population
(N ¼ 1602)
Severe pain
(n ¼ 376)
Severe discomfort
(n ¼ 507)
Severe bloating
(n ¼ 702)
All 3 symptoms
severe (n ¼ 339)
Pain
PBO mean (SE) 1.87 (0.22) 1.64 (0.19) 1.43 (0.16) 1.74 (0.24) 1.31 (0.09)
LIN mean (SE) 3.34 (0.21) 3.13 (0.18) 2.74 (0.15) 3.42 (0.23) 2.21 (0.09)
Difference 1.48 1.49 1.31 1.68 0.91
P value <.0001 <.0001 <.0001 <.0001 <.0001
Discomfort
PBO mean (SE) 1.81 (0.22) 1.77 (0.19) 1.59 (0.16) 1.69 (0.24) 1.38 (0.09)
LIN mean (SE) 3.27 (0.21) 3.28 (0.18) 2.89 (0.15) 3.37 (0.22) 2.30 (0.09)
Difference 1.46 1.51 1.29 1.68 0.93
P value <.0001 <.0001 <.0001 <.0001 <.0001
Bloating
PBO mean (SE) 1.56 (0.22) 1.57 (0.19) 1.61 (0.16) 1.49 (0.24) 1.29 (0.09)
LIN mean (SE) 3.11 (0.22) 3.10 (0.18) 2.90 (0.15) 3.23 (0.23) 2.26 (0.09)
Difference 1.54 1.54 1.29 1.73 0.98
P value <.0001 <.0001 <.0001 <.0001 <.0001
Fullness
PBO mean (SE) 1.55 (0.22) 1.54 (0.19) 1.52 (0.16) 1.46 (0.24) 1.33 (0.09)
LIN mean (SE) 3.12 (0.22) 3.14 (0.18) 2.92 (0.15) 3.22 (0.23) 2.35 (0.09)
Difference 1.57 1.61 1.40 1.77 1.02
P value <.0001 <.0001 <.0001 <.0001 <.0001
Cramping
PBO mean (SE) 1.79 (0.22) 1.67 (0.18) 1.50 (0.15) 1.72 (0.24) 1.32 (0.09)
LIN mean (SE) 3.18 (0.21) 3.04 (0.17) 2.66 (0.14) 3.27 (0.23) 2.12 (0.08)
Difference 1.38 1.38 1.16 1.55 0.80
P value <.0001 <.0001 <.0001 <.0001 <.0001
NOTE. Week 12 (LOCF) change-from-baseline least-squares means presented; P value for all analyses based on a comparison of linaclotide vs placebo in
ANCOVA model with treatment group, geographic region, and study as factors and baseline value as covariate.
LIN, linaclotide; PBO, placebo; SE, standard error.
aAssessed by using 11-point NRS: 0 ¼ none, 10 ¼ very severe.
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Approximately 50% of both linaclotide-treated and
placebo-treated patients in all the severe subpopulations
experienced at least 1 AE (Table 3). As in the safety
population, diarrhea was the most common AE in the
severe subpopulations, occurring in 18.3%–19.8% of
linaclotide-treated patients and in 1.6%–2.1% of placebo-
treated patients. Similar to rates observed in the safety
population, ﬂatulence occurred at higher rates in
linaclotide-treated (4.2%–5.7%) vs placebo-treated
(1.8%–2.5%) patients in the severe subpopulations. The
rate of abdominal pain AEs for linaclotide-treated patients
in the severe subpopulations ranged from 2.1%–4.0%
compared with 2.2%–2.5% for placebo-treated patients
and was lower compared with linaclotide-treated patients
in the safety population (5.1%).Discussion
These ﬁndings provide a new understanding of the
nature of illness in patients with IBS-C. The overall
severity of IBS comprises multiple elements, including
physical symptoms as well as health-related QOL,psychosocial factors, health-care utilization behaviors, and
burden of illness.5 Of the abdominal symptoms experi-
enced by patients, pain or discomfort is considered a
clinical hallmark of IBS and, as such, baseline abdominal
pain was an entry criterion for the two linaclotide phase 3
clinical trials. Although this trial population was selected
for pain (mean baseline abdominal pain score 3.0), a
higher proportion of patients rated abdominal bloating
and fullness as severe (44% each) than rated discomfort,
pain, or cramping as severe (32%, 23%, and 22%,
respectively) at baseline. This symptom pattern suggests
that the presence of bloating and fullness in patients with
IBS-C may warrant greater attention in clinical practice as
well as in clinical trial design. Indeed, previous analyses
have shown that abdominal pain and bloating are both
signiﬁcant predictors of overall IBS severity15 and are
both among the most frequently reported factors con-
tributing to patient perception of IBS severity.6 The pro-
portions of patients in this analysis with abdominal
symptoms rated as severe, 22%–44%, are consistent with
international survey data in which 35% of IBS patients
reported their symptoms as severe.6 Many patients in this
analysis rated more than 1 abdominal symptom as severe,
as evidenced by the considerable overlap among the se-
vere subpopulations. The multisymptom aspect of IBS in
Figure 3. Effect of linaclotide on global measures and IBS-QOL overall score in severe abdominal symptom subpopulations at
week 12. (A) Adequate relief in patients with abdominal symptom scores 7.0 at baseline (week 12 LOCF). ****P < .0001 for
linaclotide vs placebo by using a CMH test. Note: scale for adequate relief responders: yes, no (dichotomous scale). (B) Degree
of relief of IBS symptoms in patients with abdominal symptom scores 7.0 at baseline (week 12 LOCF). ****P < .0001 for
linaclotide vs placebo by using a CMH test. Note: scale for degree of relief of IBS symptoms: completely relieved, considerably
relieved, somewhat relieved, unchanged, somewhat worse, considerably worse, or as bad as I can imagine. Responders had a
degree of relief of IBS symptoms that was somewhat relieved, considerably relieved, or completely relieved (ie, 3 on the 7-
point balanced scale). (C) Treatment satisfaction in patients with abdominal symptom scores 7.0 at baseline (week 12 LOCF).
****P < .0001 for linaclotide vs placebo by using a CMH test. Note: scale for treatment satisfaction: not at all satisﬁed,
somewhat satisﬁed, moderately satisﬁed, quite satisﬁed, or very satisﬁed. Percent satisﬁed ¼ % of patients who were
moderately, quite, or very satisﬁed (ie, 3 on the 5-point ordinal scale). (D) IBS-QOL improvement in patients with abdominal
symptom scores 7.0 at baseline. Responders had a change from baseline to week 12 (LOCF) in IBS-QOL overall score of
14 points (on a 0–100 scale). **P < .01, ***P < .001, ****P < .0001 for linaclotide vs placebo by using a CMH test.
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complex disease characterized by a combination of
symptoms6 that vary over time and in severity.16
In IBS-C patients with 1 or more severe abdominal
symptoms, linaclotide signiﬁcantly improved abdominal
pain, discomfort, bloating, fullness, and cramping. In fact,
in the severe subpopulations, linaclotide treatment
resulted in greater symptom improvement from baseline
than in the ITT population, which also included patients
with milder baseline symptoms. Moreover, linaclotide
treatment resulted in greater differences from placebo in
the severe subpopulations than in the ITT population.
Thus, whereas the phase 3 clinical trials demonstrated
that linaclotide is effective in the treatment of symptoms inIBS-C patients,9,10 the current post hoc analyses further
demonstrate that linaclotide is effective in the treatment of
IBS-C patients with severe abdominal symptoms.
In addition, signiﬁcantly more linaclotide-treated
patients than placebo-treated patients were IBS-QOL
responders, indicating that in patients with severe
abdominal symptoms at baseline, linaclotide is effective
in improving IBS-related QOL in a clinically meaningful
way. Linaclotide also signiﬁcantly improved the 3 global
measures (adequate relief of IBS symptoms, degree of
relief of IBS symptoms, and treatment satisfaction) in the
severe subpopulations.
For IBS-QOL and the 3 global measures, the differences
from placebo for the severe pain and severe discomfort
Table 3. Adverse Events
Severe abdominal symptom subpopulations
Safety population
Severe
pain
Severe
discomfort Severe bloating
All 3 symptoms
severe
PBO
(n ¼ 185)
LIN
(n ¼ 192)
PBO
(n ¼ 242)
LIN
(n ¼ 266)
PBO
(n ¼ 324)
LIN
(n ¼ 379)
PBO
(n ¼ 164)
LIN
(n ¼ 176)
PBO
(n ¼ 798)
LIN
(n ¼ 807)
Patients with at
least 1 AE, n (%)
96 (51.9) 101 (52.6) 126 (52.1) 139 (52.3) 170 (52.5) 204 (53.8) 85 (51.8) 91 (51.7) 438 (54.9) 491 (60.8)
Diarrhea, n (%) 3 (1.6) 38 (19.8) 5 (2.1) 50 (18.8) 6 (1.9) 72 (19.0) 3 (1.8) 37 (21.0) 24 (3.0) 160 (19.8)
Abdominal pain, n (%) 4 (2.2) 4 (2.1) 6 (2.5) 6 (2.3) 8 (2.5) 15 (4.0) 4 (2.4) 2 (1.1) 26 (3.3) 41 (5.1)
Flatulence, n (%) 4 (2.2) 11 (5.7) 6 (2.5) 12 (4.5) 6 (1.9) 18 (4.7) 4 (2.4) 10 (5.7) 15 (1.9) 35 (4.3)
NOTE. AEs reported in 5% of linaclotide-treated patients and at incidence greater than reported in placebo-treated patients during the treatment period.
LIN, linaclotide; PBO, placebo.
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placebo for the severe bloating subpopulation, which
more closely resembled those of the ITT population. This
ﬁnding may reﬂect the baseline symptom proﬁles of these
subpopulations. In the severe pain and severe discomfort
subpopulations, mean baseline scores were severe (7.0)
not just for the eponymous symptoms but for all 5
abdominal symptoms (pain, discomfort, bloating, fullness,
and cramping), whereas in the severe bloating population,
mean baseline scores were severe for bloating, fullness,
and discomfort but not for pain (6.8) and cramping (6.5).
The rate of AEs was similar between linaclotide and
placebo groups in each of the severe subpopulations
(approximately 50%). This rate was slightly lower than
the AE rate observed for the overall safety population, in
which AEs were reported by 60.8% and 54.9% of lina-
clotide and placebo patients, respectively. Similar to the
overall safety population data, the most common AE in
the severe subgroups was diarrhea, which was reported
by 18.8%–21.0% of linaclotide-treated patients and by
1.6%–2.1% of placebo-treated patients.
The treatment of patients with severe symptoms of IBS
is challenging and is often aimed at managing individual
symptoms.16 Linaclotide not only improves severe
abdominal and bowel symptoms but also improves patient-
perceived global relief of IBS symptoms and QOL in these
patients with severe abdominal symptoms. Thus, linaclo-
tide offers an effective treatment for the overall manage-
ment of IBS-C patients with severe abdominal symptoms.
There are several important caveats to this analysis.
First, patients in these clinical trials did not rate how
bothersome their symptoms were. Therefore, it cannot be
determined how the numerical rating of symptom severity
may correlate with how bothersome a symptom is to a
patient. For example, a patient may have rated abdominal
bloating¼ 8 and abdominal pain¼ 6, but it is possible that
abdominal pain may have been more bothersome to that
patient than abdominal bloating. Second, the trial popula-
tionmay not be representative of all IBS-C patients because
entry into these trials required patients to have a meanbaseline abdominal pain score of 3.0 in addition to
meeting other inclusion and exclusion criteria.17
In summary, this analysis demonstrated that abdominal
bloating and fullness are key components of the spectrum
of illness in IBS-C, particularly in patients reporting more
severe symptoms. Those patients with severe abdominal
symptoms responded to linaclotide treatment just as well
as, if not better than, the ITT population, which included
patients with milder abdominal symptoms. Thus, linaclo-
tide can be effective in the management of IBS-C patients
with severe abdominal symptoms, including abdominal
bloating and fullness. Furthermore, linaclotide-treated pa-
tients in the severe subpopulations experienced meaningful
improvements in global measures and IBS-related QOL.References
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